Business Overview: Precision BioSciences, Inc. (NASDAQ: DTIL)

---

Executive Summary

Precision BioSciences, Inc. is a clinical-stage gene editing company built around its proprietary ARCUS® genome editing platform. Headquartered in Durham, North Carolina, and operating under a license from Duke University dating back to April 2006, Precision BioSciences develops in vivo gene editing therapies aimed at correcting disease at the DNA level, rather than just treating symptoms.

ARCUS is distinctive among gene editing platforms in a specific technical way: it is a single-protein editor that requires no guide RNA, and it is small enough that both the editor and an insertion template can fit inside the same adeno-associated virus (AAV) delivery vector — a meaningful manufacturing and delivery simplification relative to larger multi-component editing systems. Like most clinical-stage biotechs, Precision BioSciences has no approved products and no commercial revenue.

---

1. Core Business Model & How They Work

Precision BioSciences operates a mixed wholly-owned-pipeline and partnered-pipeline model, funding R&D and clinical trials through capital markets while sharing some program risk and cost through partnerships.

[ ARCUS platform R&D ] ➡️ [ Wholly-owned programs (HBV, DMD, 3243) + Partnered programs (iECURE, Caribou, TG Tx) ] ➡️ [ Phase 1/2 clinical trials ] ➡️ [ Regulatory designations (Orphan, Fast-Track, RMAT) ] ➡️ [ Approval / partnership milestones ]

Key Operational Drivers

1. Dual Wholly-Owned & Partnered Pipeline: Precision BioSciences runs its own lead in vivo programs (hepatitis B, Duchenne muscular dystrophy) while also partnering out ARCUS-based assets (e.g., with iECURE for a neonatal OTC deficiency program) — spreading both cost and risk across structures.
2. Small, Guide-RNA-Free Editor: ARCUS's compact, single-protein design is engineered specifically to solve the AAV packaging-size constraint that limits many other in vivo gene editing approaches — a deliberate design choice, not an incidental feature.
3. Regulatory Designation Strategy: the lead DMD program has already secured Rare Pediatric Disease, Orphan Drug, and Fast-Track designations, and the partnered iECURE OTC program carries RMAT designation — both signal (and partially de-risk) the regulatory pathway for ARCUS-based therapies.
4. Portfolio Prioritization: the company has already paused one program (m.3243 mitochondrial disease) to concentrate resources on its two most advanced assets, reflecting the capital discipline typical of smaller clinical-stage biotechs.

---

2. Product Portfolio (Pipeline)

Other Partnerships

Agreements with Caribou Biosciences, TG Therapeutics (azer-cel), Imugene, and Cellectis extend ARCUS licensing beyond Precision BioSciences' own pipeline. Notably, the Novartis collaboration was terminated effective January 30, 2026 — a recent, material loss of a major pharma partnership that investors should weigh carefully.

---

3. Competitive Landscape

Precision BioSciences names a dense field of gene editing competitors directly in its SEC filings:

• Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Prime Medicine, Tune Therapeutics, and Verve Therapeutics — all developing alternative gene editing approaches (base editing, CRISPR-Cas systems, prime editing) that compete for the same underlying therapeutic opportunities.
• Beyond direct gene-editing peers, Precision BioSciences also competes against entirely different modalities — gene therapy, small molecule, antibody, and protein therapies — for the same disease indications (e.g., hepatitis B has established antiviral standard-of-care competitors beyond the gene-editing field).

   GENE EDITING PLATFORM LANDSCAPE
┌──────────────────────────────────────────────────────┐
│ High │                                                 │
│  ▲   │  [CRISPR Tx]  [Intellia]   [Beam]               │
│  D   │                                                  │
│  E   │         [Editas]      [Precision Bio - ARCUS]   │
│  L   │                        (compact, guide-RNA-free)│
│  I   │  [Prime Medicine]                                │
│  V   │                      [Tune Tx]   [Verve]         │
│  E   │                                                  │
│  R   │                                                  │
│  Y   │                                                  │
│ Low  │                                                  │
│      └───────────────────────────────────────────────► │
│       Low      CLINICAL-STAGE MATURITY        High     │
└──────────────────────────────────────────────────────┘

---

4. Strategic Strengths & Risks

Strengths

• Technically differentiated editor: ARCUS's single-protein, guide-RNA-free design directly solves an AAV packaging constraint that limits competing in vivo editing platforms — a genuine engineering advantage, not just marketing framing.
• Regulatory momentum on lead assets: Rare Pediatric Disease, Orphan Drug, Fast-Track (DMD) and RMAT (partnered OTC program) designations suggest the FDA sees real unmet need and plausibility in these specific programs.
• Risk-sharing via partnerships: collaborations with iECURE, Caribou, TG Therapeutics, Imugene, and Cellectis let Precision BioSciences extend ARCUS's reach without funding every program entirely alone.
• Portfolio discipline: pausing the 3243 program to focus capital on HBV and DMD shows a willingness to prioritize rather than spread resources too thin.

Risks

• Novartis partnership termination (Jan. 2026): the loss of a major pharma collaboration is a recent, material setback — both for near-term non-dilutive funding and as a signal worth investigating further.
• Unproven platform in humans: like all gene editing approaches, ARCUS's safety and efficacy in humans remain largely unproven at scale, and novel technology risk cuts across the entire sector, not just Precision BioSciences.
• No revenue, ongoing losses: significant operating losses with no history of profitability, and a continued need for substantial additional funding to advance the pipeline.
• Heavy single-platform dependence: nearly the entire company's value depends on ARCUS working as intended; there is no second, unrelated platform to fall back on if ARCUS-specific technical or safety issues emerge.
• Dense, well-funded competitive field: Beam, CRISPR Therapeutics, Editas, Intellia, Prime Medicine, Tune, and Verve are all pursuing overlapping therapeutic opportunities, some with greater financial resources.
• Nasdaq listing and EGC-status risk: continued-listing requirements and the eventual loss of emerging growth company status (raising compliance costs) are real small-cap biotech risks.

---

5. Financial Overview

---

6. Summary Conclusion

Precision BioSciences' investment case rests on ARCUS's genuine technical differentiation — a compact, guide-RNA-free gene editor that solves a real AAV delivery constraint facing much of the in vivo gene editing field — reinforced by real regulatory momentum (Orphan, Fast-Track, RMAT designations) on its lead DMD and partnered OTC-deficiency programs. The recent termination of its Novartis collaboration in January 2026, combined with zero revenue and an unproven platform competing against seven or more well-funded gene-editing peers, means the company's near-term path depends heavily on continued execution and funding discipline around its two prioritized wholly-owned programs, HBV and DMD.